Following the announcement of positive interim clinical trial data, Merus N.V. (NASDAQ: MRUS) shares jumped 15.12% in the after-market session on Thursday, trading at $47.89.
Promising Outcomes Ahead of ASCO Presentation
Progress from the current Phase 2 study assessing the bispecific antibody petosemtamab in conjunction with pembrolizumab was revealed by Merus (MRUS). The findings, which are based on data gathered until February 27, 2025, have greatly boosted investor confidence. Dr. Carla M. L. van Herpen of Radboud University Medical Center will discuss the clinical results at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 2.
Merus claims that the combo treatment has performed better on a number of effectiveness measures than pembrolizumab monotherapy, which is now the control arm in its Phase 3 study. These findings demonstrate how petosemtamab may be able to change the accepted practice for treating head and neck squamous cell carcinoma (HNSCC), a disease with a high death rate and poor prognoses.
Key Trial Metrics and Patient Response
Of the 45 patients enrolled in the interim Phase 2 trial, 43 were eligible for an effectiveness evaluation at the time of the data cutoff. According to RECIST v1.1 criteria, Merus reported an overall response rate of 63% among them, comprising six full and 21 partial replies.
Additional analyses conducted on both first-line and second-line therapy groups supported these findings. Interestingly, individuals who had never smoked accounted for a sizable percentage of verified responses in HPV-associated p16+ oropharyngeal cancer, indicating possible biological significance in this cohort.
Looking Ahead to Phase 3 Milestones
Merus has demonstrated swift clinical execution with rapid site activation for its trials and anticipates releasing top-line interim results from one or both Phase 3 studies by 2026. MRUS also held a conference call and webcast on Thursday to further elaborate on these results and its future development roadmap.
Leave a Reply